This article was originally published in The Gray Sheet
Executive SummaryFirm will use a portion of a $7 mil. debt financing with private and institutional investors to expand international sales and marketing operations, the company reports. Remaining funds are earmarked for research and development and general capital expenditures. Investors also receive 420,000 warrants to purchase at $10 per share an equivalent number of VGI common shares through April 29, 2003. VGI has sold for clinical research use since the third quarter 1996 the OpenGene high-throughput automated clinical DNA sequencing system
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.